CAMBRIDGE, Mass., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Canaccord Genuity 33 rd Annual Growth Conference. Craig Fraser, President of Aegerion, is scheduled to present on Thursday, August 15, 2013 at 9:00 a.m. ET. The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the " Investors" section of Aegerion's website, www.aegerion.com . About Aegerion Pharmaceuticals Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases. For more information about the company, please visit www.aegerion.com .
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Manager, Investor Relations 857-242-5024